Visual summary of operating lessons from Celine Halioua.

Part 1: The Biological Thesis of Aging

  1. On the Pug and Evolutionary Selection: Celine Halioua: "You can't look at a pug and think that a pug was evolutionarily selected for it to be the optimal type of its species." — A Dog’s Life Could Hold the Key to Anti-Aging Drugs for Humans | WIRED.
  2. On Why Dogs Matter: Halioua argues that dogs are a useful model for studying aging, while any benefit of a dog therapy for humans remains unproven. — WIRED — Have a Nice Future Podcast.
  3. On Preventative Medicine: Celine Halioua: "I actually think about longevity more around this idea of preventative medicine for age related diseases." — Longevity and Biotech Fundraising with Celine Halioua (Founders in Arms transcript).
  4. On Slowing the Aging of Big Dogs: Celine Halioua: "The way to think about it is that it's slowing the rate of aging of these big dogs." — How to Build a Biotech with Celine Halioua (The Split podcast transcript).
  5. On Drugs for Quality of Life: Celine Halioua: "I think people think about it in that way because it seems so different to think about a drug from the context of not a disease, but instead just generally improving quality of life and improving health span." — A Dog’s Life Could Hold the Key to Anti-Aging Drugs for Humans | WIRED.
  6. On the Breadth of Aging Biology: Celine Halioua: "To develop a drug against ‘aging’ is one of the broadest briefs in biology." — What the Aging Field Needs.
  7. On Reducing Age-Related Disease: Halioua describes reducing the future risk of dementia, osteoarthritis, and other age-related diseases as an aspiration for longevity medicine, not an established effect of Loyal’s drugs. — WIRED — Have a Nice Future Podcast.
  8. On Aging Drugs as All-Cause Drugs: Celine Halioua: "Fundamentally, an aging drug is an all-cause mortality and morbidity drug." — What the Aging Field Needs.

Part 2: Strategic Biotech Innovation & Regulatory Navigation

  1. On Established Regulatory Paths: Celine Halioua: "If you're getting a drug approved for anti-itch or heartworm preventative, there's a very established path that has been predefined by companies before you that determines what you need to do to get approval, what the bar is, all of those things." — A Dog’s Life Could Hold the Key to Anti-Aging Drugs for Humans | WIRED.
  2. On the Regulatory Path: In her 2021 essay, Halioua wrote that there was no established regulatory path for a drug with an explicit aging label claim; this was her assessment at the time, not a claim about the current FDA position. — What the Aging Field Needs.
  3. On Patient, Rigorous Capital: Celine Halioua: "Patient, rigorous capital is key to breaking through this field." — What the Aging Field Needs.
  4. On Making the Market Comps: Celine Halioua: "Now, I have finally started to get some not-dog people to invest in the company, because I understood how to make those comps." — How to Build a Biotech with Celine Halioua (The Split podcast transcript).
  5. On the Challenge of Approving an Aging Drug: Celine Halioua: "One of the big challenges that we had to overcome—because nobody's ever gotten a drug approved for aging." — A Dog’s Life Could Hold the Key to Anti-Aging Drugs for Humans | WIRED.
  6. On Well-Funded Shots on Goal: Writing in 2021, Halioua argued that several well-funded attempts, each with more than $100 million, would be needed to give the field a chance at an aging-drug approval that decade. — What the Aging Field Needs.
  7. On Barriers to an Aging Drug: In her 2021 assessment, Halioua argued that regulatory, societal, structural, and cultural barriers—not only biological science—were impeding an aging-drug approval. — What the Aging Field Needs.
  8. On Clinically Meaningful Endpoints: Halioua says biomarkers alone did not persuade veterinarians or regulators; Loyal needed outcomes tied to objective measures of dogs’ quality of life. — WIRED — Have a Nice Future Podcast.
  9. On Blazing the Aging-Trial Path: Celine Halioua: "We need companies to take a drug that is likely to work to some clinically relevant degree and blaze this path." — What the Aging Field Needs.
  10. On Opening Up Everything: Celine Halioua: "Candidly, we're a small company, and my philosophy has always been, we want to open up everything because I think no one company is going to own the aging space." — A Dog’s Life Could Hold the Key to Anti-Aging Drugs for Humans | WIRED.

Part 3: The Philosophy of Healthspan and Autonomy

  1. On Free Will: Celine Halioua: "The way I think about it is that age-related diseases and unhealthy aging, let's call it, reduce our free will and reduce our ability to do what we want to do with our lives." — How to Build a Biotech with Celine Halioua (The Split podcast transcript).
  2. On Playing God: Celine Halioua: "I think, again, similar to the playing God philosophy, by that logic, we shouldn't have vaccines for children to prevent them from getting certain diseases." — A Dog’s Life Could Hold the Key to Anti-Aging Drugs for Humans | WIRED.
  3. On Simpler Products: Celine Halioua: "I can't control what others are working on in the longevity field, and I think one of the things I've actually spoken about in general is people building actually simpler products, because there's a direct correlation between something being complex and something being expensive." — A Dog’s Life Could Hold the Key to Anti-Aging Drugs for Humans | WIRED.
  4. On a Life Accomplishment: Celine Halioua: "I think that's a life accomplishment that I'll be very proud if we achieve it." — How to Build a Biotech with Celine Halioua (The Split podcast transcript).
  5. On Being an Animal Person: Celine Halioua: "I'm a really big animal person, which I think a lot of people don't realize." — How to Build a Biotech with Celine Halioua (The Split podcast transcript).
  6. On Ethical Debates Being Premature: Celine Halioua: "While the ethical debates may be prudent in the future, we are extremely far from these debates being relevant." — What the Aging Field Needs.
  7. On Avoiding Hype: Halioua argues that aging-drug developers should frame claims within existing regulatory standards and balance potential benefits against risks instead of relying on sweeping promises. — What the Aging Field Needs.

Part 4: Lessons on High-Impact Entrepreneurship

  1. On What Adults in the Room Know: Celine Halioua: "You tend to think that, when you're 17 or 18, that the adults in the room know what they're doing." — A Dog’s Life Could Hold the Key to Anti-Aging Drugs for Humans | WIRED.
  2. On Insular Thinking: Celine Halioua: "Insular thinking will cause us to miss the crumbs of clues strewn across all of biology." — What the Aging Field Needs.
  3. On Growth Rate Over Starting Point: Celine Halioua: "My model for myself is I start lower than most people, but my growth rate is so much higher, that I iterate into a much better place much faster." — How to Build a Biotech with Celine Halioua (The Split podcast transcript).
  4. On Needing Three Kinds of Context: Celine Halioua: "You have to have bio context, you have to have the dog context, you have to have the consumer context." — How to Build a Biotech with Celine Halioua (The Split podcast transcript).
  5. On Building Something Hard: Celine Halioua: "I think I have had so many tailwinds building Loyal, because what we're building is hard." — How to Build a Biotech with Celine Halioua (The Split podcast transcript).
  6. On the Highest Leverage Work: Celine Halioua: "The common theme of my work has been trying to find the highest leverage way to support and accelerate the first aging drug approval." — What the Aging Field Needs.
  7. On Build-to-Buy Biotechs: Celine Halioua: "Most biotech companies, whether they realize it or not at inception, are build-to-buy plays." — What the Aging Field Needs.
  8. On Not Getting Attached to Who You Are Today: Celine Halioua: "I think the minute you get attached to who you're today, it gets really difficult." — How to Build a Biotech with Celine Halioua (The Split podcast transcript).
  9. On Not Optimizing to Be a Founder: Celine Halioua: "I think it's honestly helpful to have come from a background where I never thought I'd really be a founder and I wasn't really optimizing for that." — How to Build a Biotech with Celine Halioua (The Split podcast transcript).
  10. On Hiring From Other Fields: Celine Halioua: "I have purposely hired scientists from non-aging fields – having perspectives of other fields has improved our thinking immensely." — What the Aging Field Needs.

Part 5: Socializing the Future of Longevity

  1. On Immortality: Celine Halioua: "Aging drugs are not about immortality." — What the Aging Field Needs.
  2. On Attention-Grabbing Claims: Celine Halioua: "While attention grabbing, this has set the tone of aging drugs being controversial, debatable, even unethical." — What the Aging Field Needs.
  3. On Aligned Incentives: Celine Halioua: "I've tried to build a company where our incentives are 100% aligned is what's best for the consumer." — How to Build a Biotech with Celine Halioua (The Split podcast transcript).
  4. On Investors With a High Bar: Celine Halioua: "The aging field needs more investors with a high quality bar, long time horizons, and significant capital resources." — What the Aging Field Needs.
  5. On Statins as an Analogy: Halioua uses statins as an analogy for a hoped-for medicine addressing multiple age-related conditions; she does not claim that such a broad-effect aging drug is already proven. — What the Aging Field Needs.
  6. On Not Building for the Rich: Celine Halioua: "We've been optimizing on that from day one because I don't want our products to be products for rich people or products for dogs owned by rich people—rich dogs." — A Dog’s Life Could Hold the Key to Anti-Aging Drugs for Humans | WIRED.
  7. On Higher Quality of Life: Celine Halioua: "People just actually want to have a higher quality of life, and therefore, then you also hopefully have the longer quality of life too." — How to Build a Biotech with Celine Halioua (The Split podcast transcript).
  8. On the Promise of Aging Drugs: Celine Halioua: "Aging drugs, if they live up to the fields’ dreams, could significantly improve quality of life and reduce disease burden and misery for millions of people." — What the Aging Field Needs.
  9. On Capital and the Probability of Success: Celine Halioua: "Unfortunately, in bio the probability of success is highly correlated with the amount of capital in the coffers." — What the Aging Field Needs.
  10. On Regulatory Approval: Halioua argues that therapies meant to help people must receive FDA or another regulator’s approval before they can be responsibly offered as medicines. — WIRED — Have a Nice Future Podcast.